{"id":"rovalcyte","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ROVALCYTE involves ex vivo expansion of autologous T lymphocytes derived from the patient, which are then reinfused to boost cellular immunity against cancer. The mechanism leverages the patient's own immune system by amplifying T-cell populations capable of recognizing and eliminating malignant cells. This approach is designed to provide a personalized immunotherapeutic treatment with reduced risk of graft-versus-host disease compared to allogeneic cell therapies.","oneSentence":"ROVALCYTE is an autologous T-cell therapy that expands and reinfuses a patient's own T cells to enhance anti-tumor immune response.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:32:58.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma or other solid tumors (investigational)"}]},"trialDetails":[{"nctId":"NCT05708508","phase":"PHASE3","title":"Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-03-28","conditions":"Kidney Transplant Infection","enrollment":144},{"nctId":"NCT02606266","phase":"PHASE2, PHASE3","title":"Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-07-11","conditions":"Congenital Cytomegalovirus (CMV)","enrollment":1}],"_emaApprovals":[],"_faersSignals":[{"count":126,"reaction":"NEUTROPENIA"},{"count":116,"reaction":"AGRANULOCYTOSIS"},{"count":94,"reaction":"LEUKOPENIA"},{"count":69,"reaction":"ANAEMIA"},{"count":63,"reaction":"PANCYTOPENIA"},{"count":58,"reaction":"DIARRHOEA"},{"count":57,"reaction":"ACUTE KIDNEY INJURY"},{"count":49,"reaction":"CYTOMEGALOVIRUS INFECTION"},{"count":44,"reaction":"DRUG INTERACTION"},{"count":44,"reaction":"THROMBOCYTOPENIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ROVALCYTE","genericName":"ROVALCYTE","companyName":"University Hospital, Rouen","companyId":"university-hospital-rouen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ROVALCYTE is an autologous T-cell therapy that expands and reinfuses a patient's own T cells to enhance anti-tumor immune response. Used for Metastatic melanoma or other solid tumors (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}